Business
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
Company conference call and webcast at 4:30 PM EDT NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"\nCompany conference call and webcast at 4:30 PM EDT\n\n NEW YORK--(BUSINESS WIRE)--\nLucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call on Monday, August 15, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, Chief Financial Officer, will discuss the Company’s second quarter 2022 financial results.\n\nTo access the conference call, U.S.-based listeners should dial 877-407-0789 and international listeners should dial 201-689-8562. All listeners should provide the operator with the conference call name “Lucid Business Update Conference Call” to join. Individuals interested in listening to the live conference call via the webcast may do so by visiting the investor relations section of the Company’s website at www.luciddx.com.\n\nFollowing the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within the U.S. or 412-317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 13730496. The webcast will be available for replay on the investor relations section of the Company’s website at www.luciddx.com.\n\nAbout Lucid Diagnostics\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is co...